Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 2.00
Ask: 2.15
Change: 0.055 (2.72%)
Spread: 0.15 (7.50%)
Open: 2.07
High: 2.07
Low: 1.91
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Sep 2015 07:05

RNS Number : 6273A
Immupharma PLC
30 September 2015
 

 

FOR IMMEDIATE RELEASE

30 SEPTEMBER 2015

 

 

 

TIM MCCARTHY APPOINTED AS NON-EXECUTIVE CHAIRMAN

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.

 

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

 

A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

 

 

Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:

 

"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."

 

 

Current Directorships

Ark Analytics Solutions Limited

BBN International Limited

Dropped Limited

Expedeon Holdings Limited

Frangipani Dreams Limited

Harvard Healthcare Limited

Incanthera Limited

Spear Therapeutics Limited

Unnamed Limited

Wise Old Owl Limited

 

Directorships in the Last 5 years

Retail Service Team Limited*

 

\* This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.

 

 

 

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

For further information please contact:

 

ImmuPharma plc

+ 44 (0) 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413 496

Panmure, Gordon & Co., NOMAD & Broker

+ 44 (0) 20 7886 2500

Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPKCDNOBKDNCB
Date   Source Headline
2nd Nov 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
16th Oct 20173:29 pmRNSHolding(s) in Company
4th Oct 20177:00 amRNSCompletion of Lanstead Sharing Agreement
27th Sep 20177:00 amRNSInterim Results
26th Sep 20177:00 amRNSPreparation of Lupuzor'sT Regulatory Submissions
21st Sep 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
19th Sep 20177:00 amRNSNotification of Interim Results
18th Aug 20175:09 pmRNSAIM Rule 17 Notice
12th Jul 201711:00 amRNSGrant of Options
30th Jun 201712:04 pmRNSResult of AGM
30th Jun 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
7th Jun 20177:00 amRNSAnnual Report & Notice of AGM
1st Jun 20177:00 amRNSFinal Results
22nd May 20177:00 amRNSNotification of Full Year Results
17th May 20177:00 amRNSUpdate on Lupuzor Phase III Study
31st Mar 201710:17 amRNSNew Employee Share Option Plan & Grant of Options
31st Mar 20178:33 amRNSNew Employee Share Option Plan & Grant of Options
24th Mar 20177:00 amRNSImmuPharma to present at Master Investor Show
22nd Mar 20178:51 amRNSHolding(s) in Company
20th Mar 201711:41 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20173:52 pmRNS£4.1 Million Fund Raise via Accelerated Bookbuild
10th Mar 20177:00 amRNSAccelerated Bookbuild for the Issue of Equity
6th Mar 20173:55 pmRNSHolding(s) in Company
17th Feb 20172:04 pmRNSHolding(s) in Company
25th Jan 20177:00 amRNSUpdate on Lupuzor Phase III Study
24th Jan 20177:00 amRNSChange of Adviser
29th Dec 201610:54 amRNSHolding(s) in Company
22nd Dec 20167:00 amRNSUpdate on Lupuzor Pivotal Phase III Study
16th Nov 20167:00 amRNSUpdate on Cancer Compound IPP-204106 'Nucant'
9th Nov 20167:00 amRNSHolding(s) in Company
26th Oct 20163:42 pmRNSHolding(s) in Company
21st Oct 20165:13 pmRNSClose of Accelerated Bookbuild
21st Oct 20161:33 pmRNSProposed Accelerated Bookbuild for Vendor Placing
30th Sep 20167:00 amRNSHalf-year Report
14th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
7th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
21st Jul 20168:32 amRNSHolding(s) in Company
1st Jul 20163:52 pmRNSHolding(s) in Company
27th Jun 20164:41 pmRNSSecond Price Monitoring Extn
27th Jun 20164:35 pmRNSPrice Monitoring Extension
20th Jun 20167:00 amRNSAppointment of Joint Broker
9th Jun 20165:56 pmRNSHolding(s) in Company
8th Jun 20167:00 amRNSSymposium with Lupuzors Inventor Prof. S Muller
7th Jun 20167:00 amRNSEuropean Patients Commence Dosing in Lupuzor
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.